10-K
Annual Report
60 DEGREES PHARMACEUTICALS, INC.
SXTPW
NASDAQ
CIK: 1946563
File #: 001-41719
Balance Sheet
46 line items · 2 periods
XBRL
| Item | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|
Current Assets: | ||
Cash and Cash Equivalents | 1,659,353 | 2,142,485 |
Accounts Receivable | 486,748 | 231,332 |
Prepaid and Other Assets | 1,068,940 | 4,402,602 |
Short-Term Investments | 1,728,472 | — |
Inventory (Note 3) | 442,764 | 466,169 |
Total Current Assets | 5,386,277 | 7,242,588 |
Property and Equipment, net (Note 4) | 149,808 | 57,761 |
Other Assets: | ||
Right of Use Asset (Note 11) | — | 13,517 |
Long-Term Prepaid Expense | 66,176 | 242,647 |
Intangible Assets, net (Note 5) | 157,084 | 227,258 |
Total Other Assets | 223,260 | 483,422 |
Total Assets | 5,759,345 | 7,783,771 |
Current Liabilities: | ||
Accounts Payable and Accrued Expenses | 1,007,618 | 506,206 |
Lease Liability (Note 11) | — | 13,650 |
SBA EIDL (including accrued interest) (Note 7) | 8,772 | 8,772 |
Derivative Liabilities (Note 8) | 640,830 | 2,306,796 |
Fair Value, Inputs, Level 3 - Derivative Liabilities | 640,830 | 2,306,796 |
Derivative Liabilities | 640,830 | 2,306,796 |
Fair Value, Inputs, Level 3 | 640,830 | 2,306,796 |
Contingent Milestone Payment - Fair Value, Inputs, Level 3 - Fair Value, Recurring | 640,830 | 2,306,796 |
Fair Value, Inputs, Level 3 - Fair Value, Recurring | 640,830 | 2,306,796 |
Total Current Liabilities | 1,657,220 | 2,835,424 |
Long-Term Liabilities: | ||
SBA EIDL (including accrued interest) (Note 7) | 147,119 | 150,251 |
Total Long-Term Liabilities | 147,119 | 150,251 |
Total Liabilities | 1,804,339 | 2,985,675 |
SHAREHOLDERS’ EQUITY: | ||
Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 and 78,803 issued and outstanding as of December 31, 2024 and December 31, 2023, respectively (Note 6) | 9,567,439 | 9,858,040 |
Common Stock, $0.0001 par value, 150,000,000 shares authorized; 566,908 and 96,847 issued and outstanding as of December 31, 2024 and December 31, 2023, respectively (Note 6) | 57 | 10 |
Additional Paid-in Capital | 34,860,590 | 27,457,373 |
Accumulated Other Comprehensive Income | 135,471 | 135,561 |
Accumulated Deficit | (40,527,957) | (32,580,850) |
60P Shareholders’ Equity: | 4,035,600 | 4,870,134 |
Noncontrolling Interest | (80,594) | (72,038) |
Total Shareholders’ Equity | 3,955,006 | 4,798,096 |
Series A - Preferred Stock | 9,567,439 | 9,858,040 |
Common Stock | 57 | 10 |
Additional Paid-In Capital | 34,860,590 | 27,457,373 |
Accumulated Deficit | (40,527,957) | (32,580,850) |
Accumulated Other Comprehensive Income (Loss) | 135,471 | 135,561 |
Total Shareholders’ Equity (Deficit) Attributable to 60P | 4,035,600 | 4,870,134 |
Noncontrolling Interest on Shareholders | (80,594) | (72,038) |
Total Liabilities and Shareholders’ Equity | 5,759,345 | 7,783,771 |